Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

The Impact of Plasma-Derived Microvesicles from a Femoral Fracture Animal Model on Osteoblast Function.

Qiao Z, Wang W, Luo P, Hofman M, Horst K, Müller-Newen G, Greven J, Hildebrand F.

Shock. 2019 Feb 26. doi: 10.1097/SHK.0000000000001336. [Epub ahead of print]

PMID:
31157718
2.

Novel 3D analysis using optical tissue clearing documents the evolution of murine rapidly progressive glomerulonephritis.

Puelles VG, Fleck D, Ortz L, Papadouri S, Strieder T, Böhner AMC, van der Wolde JW, Vogt M, Saritas T, Kuppe C, Fuss A, Menzel S, Klinkhammer BM, Müller-Newen G, Heymann F, Decker L, Braun F, Kretz O, Huber TB, Susaki EA, Ueda HR, Boor P, Floege J, Kramann R, Kurts C, Bertram JF, Spehr M, Nikolic-Paterson DJ, Moeller MJ.

Kidney Int. 2019 Mar 15. pii: S0085-2538(19)30318-7. doi: 10.1016/j.kint.2019.02.034. [Epub ahead of print]

PMID:
31155155
3.

Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling.

Kuepper MK, Bütow M, Herrmann O, Ziemons J, Chatain N, Maurer A, Kirschner M, Maié T, Costa IG, Eschweiler J, Koschmieder S, Brümmendorf TH, Müller-Newen G, Schemionek M.

Leukemia. 2019 Mar 6. doi: 10.1038/s41375-019-0427-7. [Epub ahead of print]

PMID:
30842608
4.

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.

Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S.

Leukemia. 2019 Apr;33(4):995-1010. doi: 10.1038/s41375-018-0295-6. Epub 2018 Nov 23.

PMID:
30470838
5.

Biological Activation of Bioinert Medical High-Performance Oxide Ceramics by Hydrolytically Stable Immobilization of c(RGDyK) and BMP-2.

Böke F, Labude N, Lauria I, Ernst S, Müller-Newen G, Neuss S, Fischer H.

ACS Appl Mater Interfaces. 2018 Nov 14;10(45):38669-38680. doi: 10.1021/acsami.8b08900. Epub 2018 Nov 5.

PMID:
30280884
6.

Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.

Sonntag R, Giebeler N, Nevzorova YA, Bangen JM, Fahrenkamp D, Lambertz D, Haas U, Hu W, Gassler N, Cubero FJ, Müller-Newen G, Abdallah AT, Weiskirchen R, Ticconi F, Costa IG, Barbacid M, Trautwein C, Liedtke C.

Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9282-9287. doi: 10.1073/pnas.1807155115. Epub 2018 Aug 27.

7.

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R.

Cell Stem Cell. 2018 Aug 2;23(2):308-309. doi: 10.1016/j.stem.2018.07.006. No abstract available.

PMID:
30075132
8.

Nucleolar-nucleoplasmic shuttling of TARG1 and its control by DNA damage-induced poly-ADP-ribosylation and by nucleolar transcription.

Bütepage M, Preisinger C, von Kriegsheim A, Scheufen A, Lausberg E, Li J, Kappes F, Feederle R, Ernst S, Eckei L, Krieg S, Müller-Newen G, Rossetti G, Feijs KLH, Verheugd P, Lüscher B.

Sci Rep. 2018 Apr 30;8(1):6748. doi: 10.1038/s41598-018-25137-w.

9.

Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism.

Widowati EW, Ernst S, Hausmann R, Müller-Newen G, Becker W.

Biol Open. 2018 Apr 26;7(4). pii: bio032862. doi: 10.1242/bio.032862.

10.

Heparan Sulfate Induces Necroptosis in Murine Cardiomyocytes: A Medical-In silico Approach Combining In vitro Experiments and Machine Learning.

Zechendorf E, Vaßen P, Zhang J, Hallawa A, Martincuks A, Krenkel O, Müller-Newen G, Schuerholz T, Simon TP, Marx G, Ascheid G, Schmeink A, Dartmann G, Thiemermann C, Martin L.

Front Immunol. 2018 Mar 20;9:393. doi: 10.3389/fimmu.2018.00393. eCollection 2018.

11.

Surface Topography Guides Morphology and Spatial Patterning of Induced Pluripotent Stem Cell Colonies.

Abagnale G, Sechi A, Steger M, Zhou Q, Kuo CC, Aydin G, Schalla C, Müller-Newen G, Zenke M, Costa IG, van Rijn P, Gillner A, Wagner W.

Stem Cell Reports. 2017 Aug 8;9(2):654-666. doi: 10.1016/j.stemcr.2017.06.016. Epub 2017 Jul 27.

12.

Erratum: Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788d. No abstract available.

PMID:
28586341
13.

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R.

Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8. doi: 10.1016/j.stem.2017.03.008. Epub 2017 Apr 27. Erratum in: Cell Stem Cell. 2018 Aug 2;23(2):308-309.

14.

Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, Coccia M, Görtz D, This S, Stockenhuber K, Pott J, Friedrich M, Ryzhakov G, Baribaud F, Brodmerkel C, Cieluch C, Rahman N, Müller-Newen G, Owens RJ, Kühl AA, Maloy KJ, Plevy SE; Oxford IBD Cohort Investigators, Keshav S, Travis SPL, Powrie F.

Nat Med. 2017 May;23(5):579-589. doi: 10.1038/nm.4307. Epub 2017 Apr 3. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

15.

Development of platelets during steady state and inflammation.

Müller-Newen G, Stope MB, Kraus T, Ziegler P.

J Leukoc Biol. 2017 May;101(5):1109-1117. doi: 10.1189/jlb.1RU0916-391RR. Epub 2017 Feb 24. Review.

PMID:
28235774
16.

Nuclear translocation of STAT3 and NF-κB are independent of each other but NF-κB supports expression and activation of STAT3.

Martincuks A, Andryka K, Küster A, Schmitz-Van de Leur H, Komorowski M, Müller-Newen G.

Cell Signal. 2017 Apr;32:36-47. doi: 10.1016/j.cellsig.2017.01.006. Epub 2017 Jan 9.

PMID:
28089769
17.

Assessing the Intracellular Integrity of Phosphine-Stabilized Ultrasmall Cytotoxic Gold Nanoparticles Enabled by Fluorescence Labeling.

Broda J, Küster A, Westhues S, Fahrenkamp D, Vogg AT, Steitz J, Mottaghy FM, Müller-Newen G, Simon U.

Adv Healthc Mater. 2016 Dec;5(24):3118-3128. doi: 10.1002/adhm.201600892. Epub 2016 Nov 18.

PMID:
27860428
18.

Intramolecular hydrophobic interactions are critical mediators of STAT5 dimerization.

Fahrenkamp D, Li J, Ernst S, Schmitz-Van de Leur H, Chatain N, Küster A, Koschmieder S, Lüscher B, Rossetti G, Müller-Newen G.

Sci Rep. 2016 Oct 18;6:35454. doi: 10.1038/srep35454.

19.

The synthetic antimicrobial peptide 19-2.5 attenuates mitochondrial dysfunction in cardiomyocytes stimulated with human sepsis serum.

Martin L, Peters C, Heinbockel L, Moellmann J, Martincuks A, Brandenburg K, Lehrke M, Müller-Newen G, Marx G, Schuerholz T.

Innate Immun. 2016 Nov;22(8):612-619. doi: 10.1177/1753425916667474. Epub 2016 Sep 21.

PMID:
27624711
20.

Dissecting functions of the N-terminal domain and GAS-site recognition in STAT3 nuclear trafficking.

Martincuks A, Fahrenkamp D, Haan S, Herrmann A, Küster A, Müller-Newen G.

Cell Signal. 2016 Aug;28(8):810-25. doi: 10.1016/j.cellsig.2016.03.011. Epub 2016 Mar 31.

PMID:
27040695
21.

Proteolytic Cleavage Governs Interleukin-11 Trans-signaling.

Lokau J, Nitz R, Agthe M, Monhasery N, Aparicio-Siegmund S, Schumacher N, Wolf J, Möller-Hackbarth K, Waetzig GH, Grötzinger J, Müller-Newen G, Rose-John S, Scheller J, Garbers C.

Cell Rep. 2016 Feb 23;14(7):1761-1773. doi: 10.1016/j.celrep.2016.01.053. Epub 2016 Feb 11.

22.

Soluble Heparan Sulfate in Serum of Septic Shock Patients Induces Mitochondrial Dysfunction in Murine Cardiomyocytes.

Martin L, Peters C, Schmitz S, Moellmann J, Martincuks A, Heussen N, Lehrke M, Müller-Newen G, Marx G, Schuerholz T.

Shock. 2015 Dec;44(6):569-77. doi: 10.1097/SHK.0000000000000462.

PMID:
26529654
23.

Telomere shortening in enterocytes of patients with uncontrolled acute intestinal graft-versus-host disease.

Hummel S, Ventura Ferreira MS, Heudobler D, Huber E, Fahrenkamp D, Gremse F, Schmid K, Müller-Newen G, Ziegler P, Jost E, Blasco MA, Brümmendorf TH, Holler E, Beier F.

Blood. 2015 Nov 26;126(22):2518-21. doi: 10.1182/blood-2015-03-633289. Epub 2015 Oct 20.

24.

Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery.

Görtz D, Braun GS, Maruta Y, Djudjaj S, van Roeyen CR, Martin IV, Küster A, Schmitz-Van de Leur H, Scheller J, Ostendorf T, Floege J, Müller-Newen G.

Sci Rep. 2015 Oct 1;5:14685. doi: 10.1038/srep14685.

25.

MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis.

Alampour-Rajabi S, El Bounkari O, Rot A, Müller-Newen G, Bachelerie F, Gawaz M, Weber C, Schober A, Bernhagen J.

FASEB J. 2015 Nov;29(11):4497-511. doi: 10.1096/fj.15-273904. Epub 2015 Jul 2.

PMID:
26139098
26.

Angptl4 is upregulated under inflammatory conditions in the bone marrow of mice, expands myeloid progenitors, and accelerates reconstitution of platelets after myelosuppressive therapy.

Schumacher A, Denecke B, Braunschweig T, Stahlschmidt J, Ziegler S, Brandenburg LO, Stope MB, Martincuks A, Vogt M, Görtz D, Camporeale A, Poli V, Müller-Newen G, Brümmendorf TH, Ziegler P.

J Hematol Oncol. 2015 Jun 9;8:64. doi: 10.1186/s13045-015-0152-2.

27.

Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.

Fahrenkamp D, de Leur HS, Küster A, Chatain N, Müller-Newen G.

Cell Commun Signal. 2015 Feb 15;13:10. doi: 10.1186/s12964-014-0081-7.

28.

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.

Schneider RK, Ziegler S, Leisten I, Ferreira MS, Schumacher A, Rath B, Fahrenkamp D, Müller-Newen G, Crysandt M, Wilop S, Jost E, Koschmieder S, Knüchel R, Brümmendorf TH, Ziegler P.

J Hematol Oncol. 2014 Dec 14;7:92. doi: 10.1186/s13045-014-0092-2.

29.

Caspase-8-mediated PAR-4 cleavage is required for TNFα-induced apoptosis.

Treude F, Kappes F, Fahrenkamp D, Müller-Newen G, Dajas-Bailador F, Krämer OH, Lüscher B, Hartkamp J.

Oncotarget. 2014 May 30;5(10):2988-98.

30.

Gp130-dependent signaling in the podocyte.

Nagayama Y, Braun GS, Jakobs CM, Maruta Y, van Roeyen CR, Klinkhammer BM, Boor P, Villa L, Raffetseder U, Trautwein C, Görtz D, Müller-Newen G, Ostendorf T, Floege J.

Am J Physiol Renal Physiol. 2014 Aug 1;307(3):F346-55. doi: 10.1152/ajprenal.00620.2013. Epub 2014 Jun 4.

31.

Arginine residues within the DNA binding domain of STAT3 promote intracellular shuttling and phosphorylation of STAT3.

Ginter T, Fahrer J, Kröhnert U, Fetz V, Garrone A, Stauber RH, Reichardt W, Müller-Newen G, Kosan C, Heinzel T, Krämer OH.

Cell Signal. 2014 Aug;26(8):1698-706. doi: 10.1016/j.cellsig.2014.03.033. Epub 2014 Apr 8.

PMID:
24721162
32.

Intracellular signaling prevents effective blockade of oncogenic gp130 mutants by neutralizing antibodies.

Rinis N, Küster A, Schmitz-Van de Leur H, Mohr A, Müller-Newen G.

Cell Commun Signal. 2014 Mar 10;12:14. doi: 10.1186/1478-811X-12-14.

33.

Consequences of the disease-related L78R mutation for dimerization and activity of STAT3.

Domoszlai T, Martincuks A, Fahrenkamp D, Schmitz-Van de Leur H, Küster A, Müller-Newen G.

J Cell Sci. 2014 May 1;127(Pt 9):1899-910. doi: 10.1242/jcs.137422. Epub 2014 Feb 25.

34.

Mutations in the interleukin receptor IL11RA cause autosomal recessive Crouzon-like craniosynostosis.

Keupp K, Li Y, Vargel I, Hoischen A, Richardson R, Neveling K, Alanay Y, Uz E, Elcioğlu N, Rachwalski M, Kamaci S, Tunçbilek G, Akin B, Grötzinger J, Konas E, Mavili E, Müller-Newen G, Collmann H, Roscioli T, Buckley MF, Yigit G, Gilissen C, Kress W, Veltman J, Hammerschmidt M, Akarsu NA, Wollnik B.

Mol Genet Genomic Med. 2013 Nov;1(4):223-37. doi: 10.1002/mgg3.28. Epub 2013 Aug 19.

35.

Characterization of SLCO5A1/OATP5A1, a solute carrier transport protein with non-classical function.

Sebastian K, Detro-Dassen S, Rinis N, Fahrenkamp D, Müller-Newen G, Merk HF, Schmalzing G, Zwadlo-Klarwasser G, Baron JM.

PLoS One. 2013 Dec 20;8(12):e83257. doi: 10.1371/journal.pone.0083257. eCollection 2013.

36.

Dominant-negative activity of the STAT3-Y705F mutant depends on the N-terminal domain.

Mohr A, Fahrenkamp D, Rinis N, Müller-Newen G.

Cell Commun Signal. 2013 Nov 5;11:83. doi: 10.1186/1478-811X-11-83.

37.

Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.

Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G, Jove R.

Cancer Res. 2014 Feb 15;74(4):1227-37. doi: 10.1158/0008-5472.CAN-13-0594. Epub 2013 Oct 31.

38.

Fluorescent SNAP-tag galectin fusion proteins as novel tools in glycobiology.

Kupper CE, Böcker S, Liu H, Adamzyk C, van de Kamp J, Recker T, Lethaus B, Jahnen-Dechent W, Neuss S, Müller-Newen G, Elling L.

Curr Pharm Des. 2013;19(30):5457-67.

PMID:
23431989
39.

Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts.

Seikrit C, Henkel C, van Roeyen CR, Bokemeyer D, Eitner F, Martin IV, Boor P, Knüchel R, Meyer HE, Müller-Newen G, Eriksson U, Floege J, Ostendorf T.

Nephrol Dial Transplant. 2013 Apr;28(4):889-900. doi: 10.1093/ndt/gfs509. Epub 2012 Dec 9.

PMID:
23229927
40.

Two distinct types of Langerhans cells populate the skin during steady state and inflammation.

Seré K, Baek JH, Ober-Blöbaum J, Müller-Newen G, Tacke F, Yokota Y, Zenke M, Hieronymus T.

Immunity. 2012 Nov 16;37(5):905-16. doi: 10.1016/j.immuni.2012.07.019.

41.

Dynamic subcellular localization of the mono-ADP-ribosyltransferase ARTD10 and interaction with the ubiquitin receptor p62.

Kleine H, Herrmann A, Lamark T, Forst AH, Verheugd P, Lüscher-Firzlaff J, Lippok B, Feijs KL, Herzog N, Kremmer E, Johansen T, Müller-Newen G, Lüscher B.

Cell Commun Signal. 2012 Sep 20;10(1):28. doi: 10.1186/1478-811X-10-28.

42.

Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.

Chatain N, Ziegler P, Fahrenkamp D, Jost E, Moriggl R, Schmitz-Van de Leur H, Müller-Newen G.

Oncogene. 2013 Aug 1;32(31):3587-97. doi: 10.1038/onc.2012.369. Epub 2012 Aug 27.

PMID:
22926520
43.

Plasticity and cross-talk of interleukin 6-type cytokines.

Garbers C, Hermanns HM, Schaper F, Müller-Newen G, Grötzinger J, Rose-John S, Scheller J.

Cytokine Growth Factor Rev. 2012 Jun;23(3):85-97. doi: 10.1016/j.cytogfr.2012.04.001. Epub 2012 May 15. Review.

PMID:
22595692
44.

Cytokines and inflammation.

Floege J, Lüscher B, Müller-Newen G.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):427. doi: 10.1016/j.ejcb.2012.01.003. Epub 2012 Feb 23. No abstract available.

PMID:
22365147
45.

Dynamics and non-canonical aspects of JAK/STAT signalling.

Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, Vogt M, Müller-Newen G.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):524-32. doi: 10.1016/j.ejcb.2011.09.005. Epub 2011 Oct 21. Review.

PMID:
22018664
46.

Receptor fusion proteins for the inhibition of cytokines.

Schwache D, Müller-Newen G.

Eur J Cell Biol. 2012 Jun-Jul;91(6-7):428-34. doi: 10.1016/j.ejcb.2011.07.008. Epub 2011 Sep 29. Review.

PMID:
21958554
47.

Small-fiber neuropathy in patients with ALS.

Weis J, Katona I, Müller-Newen G, Sommer C, Necula G, Hendrich C, Ludolph AC, Sperfeld AD.

Neurology. 2011 Jun 7;76(23):2024-9. doi: 10.1212/WNL.0b013e31821e553a.

PMID:
21646630
48.

Directed covalent immobilization of fluorescently labeled cytokines.

Recker T, Haamann D, Schmitt A, Küster A, Klee D, Barth S, Müller-Newen G.

Bioconjug Chem. 2011 Jun 15;22(6):1210-20. doi: 10.1021/bc200079e. Epub 2011 May 11.

PMID:
21528930
49.

The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3.

Vogt M, Domoszlai T, Kleshchanok D, Lehmann S, Schmitt A, Poli V, Richtering W, Müller-Newen G.

J Cell Sci. 2011 Mar 15;124(Pt 6):900-9. doi: 10.1242/jcs.072520. Epub 2011 Feb 15.

50.

A receptor fusion protein for the inhibition of murine oncostatin M.

Brolund L, Küster A, Korr S, Vogt M, Müller-Newen G.

BMC Biotechnol. 2011 Jan 11;11:3. doi: 10.1186/1472-6750-11-3.

Supplemental Content

Loading ...
Support Center